EcoR1 Capital LLC lifted its holdings in Galapagos NV (NASDAQ:GLPG) by 5.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 578,505 shares of the biotechnology company’s stock after purchasing an additional 27,464 shares during the period. Galapagos NV comprises 7.9% of EcoR1 Capital LLC’s holdings, making the stock its 5th biggest position. EcoR1 Capital LLC’s holdings in Galapagos NV were worth $44,267,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new stake in shares of Galapagos NV in the 1st quarter worth approximately $161,000. Acadian Asset Management LLC purchased a new stake in shares of Galapagos NV in the 2nd quarter worth approximately $166,000. New York State Common Retirement Fund purchased a new stake in shares of Galapagos NV in the 2nd quarter worth approximately $166,000. Pacad Investment Ltd. purchased a new stake in shares of Galapagos NV in the 2nd quarter worth approximately $168,000. Finally, Cim Investment Mangement Inc. purchased a new stake in shares of Galapagos NV in the 1st quarter worth approximately $203,000. 23.62% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Galapagos NV (GLPG) is EcoR1 Capital LLC’s 5th Largest Position” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/galapagos-nv-glpg-is-ecor1-capital-llcs-5th-largest-position/1615666.html.

GLPG has been the subject of several research reports. Zacks Investment Research raised shares of Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a research report on Friday, July 14th. Royal Bank Of Canada initiated coverage on shares of Galapagos NV in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $98.00 price target for the company. BTIG Research reaffirmed a “buy” rating and issued a $98.00 price target on shares of Galapagos NV in a research report on Thursday, July 20th. Nomura lowered their price target on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating for the company in a research report on Thursday, June 22nd. Finally, BidaskClub cut shares of Galapagos NV from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Galapagos NV has a consensus rating of “Buy” and a consensus price target of $108.14.

Galapagos NV (GLPG) traded down 0.95% on Friday, hitting $101.63. 40,792 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $101.25 and its 200-day moving average price is $101.25. Galapagos NV has a 12-month low of $57.16 and a 12-month high of $103.97.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Institutional Ownership by Quarter for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.